Consensus $2.16. Backs FY25 revenue view $940M-$955M, consensus $949.17M. The company said, “Inspire is maintaining its full year 2025 revenue guidance of between $940 million to $955 million, which represents growth of 17% to 19% over full year 2024 revenue of $802.8 million. The company is maintaining its full year 2025 gross margin guidance of 84% to 86%. Inspire is increasing diluted net income per share guidance for the full year 2025 to between $2.20 to $2.30. This compares to the prior guidance of $2.10 to $2.20 per share.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical Systems Reports Strong Q1 2025 Revenue Growth
- INSP Earnings this Week: How Will it Perform?
- Inspire Medical price target lowered to $175 from $190 at Stifel
- Nyxoah price target lowered to $14 from $15 at Stifel
- Inspire Medical adds Paul Hoff, Ruchir Patel as VP, senior medical directors